Effect of Electromagnetic Therapy on Patients With Chronic Rhinosinusitis.

Cairo University37 enrolled

Overview

This study aimed to evaluate the efficacy of Pulsed electromagnetic field (PEMF) for Chronic sinusitis in a randomized, double-blind, placebo-controlled trial.

Chronic sinusitis, or chronic rhinosinusitis, is an inflammatory condition defined by symptomatic inflammation of the paranasal sinuses lasting longer than 3 months. Common presenting symptoms include nasal obstruction, facial pressure or fullness, nasal discharge (anterior or posterior), and olfactory loss. Furthermore, chronic sinusitis is associated with reductions in patient quality of life, sleep quality, and daily productivity. A pulsed electromagnetic field (PEMF) has an anti-inflammatory, antimicrobial, and improves the microcirculation of the mucosal membrane of the nasal cavity. It has been suggested that magnetic therapy can be used in treating chronic sinusitis but there is a scarce of studies about its usage.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Magnetic Therapy Rhinosinusitis Headache Fatigue

Interventions

Pulsed electromagnetic fieldDEVICE

Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients suffering from mild to moderate symptoms of rhinosinusitis. Exclusion Criteria: * pregnant or breastfeeding women. * patients with definite deviated nasal septum, sinusitis, or history of operation within the last 6 months. * patients with hypertension, diabetes mellitus, malignancy, active pulmonary tuberculosis, infection, active respiratory disease like asthma, or other systemic diseases. * patients with long-term use of corticosteroids or immunosuppressive agents. * patients who were involved in another clinical study within 30 days. * patients who were unable to comply with the follow-up schedules. * patients who had used antihistamines within 1 week, topical corticosteroids within 2 weeks, systemic corticosteroids within 4 weeks, anti-cholinergic drugs within 3 days, antileukotriene drugs within 1 week, decongestants within 3 days, tricyclic antidepressants or phenothiazines within 2 weeks, non-steroidal analgesics within 2 weeks, and other drugs which the researchers believed were inappropriate.

Locations (1)

Faculty of physical therapy, Cairo university

Giza, Dokki, Egypt

Outcomes

Primary Outcomes

Headache

Headache was measured using VAS at the beginning and end of the intervention. The scale ranged from zero to 10. The higher the scale the higher the headache.

Time frame: Baseline and one month.

Secondary Outcomes

Fatigue

Fatigue was measured using fatigue scale at the beginning and end of the intervention. The scale ranged from zero to 10. The higher the scale the higher the fatigue value

Time frame: Baseline and one month.

CT finding

Number of sinus opacifications before and after intervention.

Time frame: Baseline and one month.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.